| Patient | Dwight D. Eisenhower |
|---|---|
| Date of birth | 1960-10-14 |
| Identifiers | MRN HR-ET015-SYN; SSN (made up) 000-15-2673 |
| Document date | 2026-05-11 |
| Author | Russell Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Seven-month coronary disease review. [S]
Mr. Eisenhower returns for his seven-month review. He works full time, travels most weeks, and plays golf twice a week, walking the course, without chest pain or breathlessness. The right-sided nosebleed four weeks ago has not recurred after cautery, and he stopped the petroleum jelly after two weeks. He continues every dose of aspirin and ticagrelor. His home blood pressure averages 120/74 and he has lost 1.5 kg since January. [S]
| Element | Detail |
|---|---|
| Interval change | Full activity including golf; no angina |
| Nosebleed | No recurrence since cautery four weeks ago |
| Home blood pressure | Average 120/74 |
| Weight | Down 1.5 kg since January |
| Nitroglycerin use | None |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Good energy; intentional weight loss |
| Ears, nose, mouth, and throat | Negative | No further nosebleeds |
| Cardiovascular | Negative | No chest pain, palpitations, or edema |
| Respiratory | Negative | No breathlessness walking the golf course |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Ticagrelor 90 mg oral tablet, one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 2025-09-24 to 2026-09-28 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-24 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-25 | active | S |
| Lisinopril 5 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2025-09-26 to 2026-01-12 | completed | S |
| Lisinopril 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 2025-09-24 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-11 | Body height | 178 | cm | S |
| 2026-05-11 | Body weight | 77.4 | kg | S |
| 2026-05-11 | Body mass index (BMI) [Ratio] | 24.4 | kg/m2 | S |
| 2026-05-11 | Systolic blood pressure | 122 | mm[Hg] | S |
| 2026-05-11 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 2026-05-11 | Heart rate | 58 | /min | S |
| 2026-05-11 | Respiratory rate | 14 | /min | S |
| 2026-05-11 | Body temperature | 36.6 | Cel | S |
| 2026-05-11 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-11 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-05-11; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well, tanned from golf |
| Nose | Right anterior septum healed |
| Heart | Regular rhythm; no murmur or gallop |
| Lungs | Clear |
| Extremities | No edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Anterior ST-elevation myocardial infarction about four months before intake, treated with a drug-eluting stent to the left anterior descending artery; synthetic modern episode linked to the documented 1955 anterolateral infarction | active | confirmed | I25.2 | S — Synthetic modern diagnosis; the 1955 infarction remains D in the history. |
| Coronary artery disease, single-vessel, after stenting; no angina | active | confirmed | I25.10 | S — Synthetic diagnosis supporting secondary prevention. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
| Essential hypertension | active | confirmed | I10 | S — Synthetic diagnosis; no blood pressure from his lifetime is used. |
| Former heavy cigarette smoker, quit about seven years before intake | active | confirmed | Z87.891 | S — Synthetic coded history echoing the documented heavy smoking and quitting around 1949. |
| Anterior epistaxis, right side, on dual antiplatelet therapy; controlled with silver nitrate cautery | resolved | confirmed | R04.0 | S — Synthetic intercurrent illness at an unscheduled visit; it does not echo a documented illness. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure, heart rate, weight and BMI, heart and lungs, edema | Every visit | Completed today | Blood pressure 122/74 mmHg, weight 77.4 kg, BMI 24.4 |
| Medication safety | Dual antiplatelet therapy adherence and bleeding | Every visit | Completed today | Taking all doses; one anterior nosebleed four weeks ago, controlled with cautery, without recurrence |
| Medication safety | Statin, beta-blocker, and ACE inhibitor adherence | Every visit | Completed today | Taking all doses |
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing an ACE inhibitor, then every 6 months | Due | Due in July; order given to draw before the one-year review |
| Laboratory | Lipid panel | 4 to 12 weeks after starting or changing therapy, then every 3 to 12 months | Up to date | LDL cholesterol 50 mg/dL in March; next at the one-year review |
| Survey | Depression screen (PHQ-2) | Every visit | Completed today | Score 0 |
| Self-management | Tobacco use | Every visit | Completed today | Abstinent |
| Self-management | Physical activity and diet | Every visit | Completed today | Golf twice a week walking the course; brisk walks on other days |
| Examination | Clinical follow-up visit | Every 4 to 6 months in the first year | Completed today | Next at one year, when the antiplatelet plan changes |
Goal progress:
Guideline basis: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, acute myocardial infarction, ischemic heart disease, hyperlipidemia, and hypertension monographs (2026)
Follow-up: One-year review in about four and a half months, with a lipid panel and basic metabolic panel. Next scheduled visit 2026-09-28: one-year review after myocardial infarction: end of dual antiplatelet therapy. [S]